Page 46 - Early Access Program News Today

Published: Jan 27, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT’s Marketing Authorization Application (MAA) for Oxbryta ® (voxelotor) tablets and started its standard review process. GBT is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with sickle cell disease (SCD) who are...

Cepton introduces the world’s smallest wide field of view lidar sensor for near-range applications Cepton’s miniature Nova lidar is easy to embed anywhere and costs less than $100 in high automotive volumes San Jose, California USA – January 14, 2021 – Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced its path-breaking miniature lidar sensor – the Nova – priced at less than $100 for high volume automotive applicatio...

Cepton's miniature Nova lidar is easy to embed anywhere and costs less than $100 in high automotive volumes Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based

DGAP-News: AiCuris Anti-infective Cures GmbH / Key word(s): Conference AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference 08.01.2021 / 12:15 AiCuris to Present at the 39 th Annual J.P. Morgan Healthcare Conference WUPPERTAL, Germany, January 08, 2021 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that Dr. Holger Zimmermann, CEO of AiCuris, will present at the 39th Annual J.P. ...

Company Podcast Scheduled for Engineers, Editors, Analysts, and Investors ALISO VIEJO, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Company will provide a Podcast Tuesday 12 January 2021 at 4:00 p.m. U.S. PST. The BrainChip Podcast will continue as a monthly event and is intended to provide insight on the Company’s strategy and progress for the engineering commu...

Story Realme 7, Narzo 20 Pro, X2 Pro, and 6 Pro now receiving Android 11-based Realme UI 2.0 betas If you are a user of one of these Realme smartphones, you can head to the company website and register for the beta programme. Shubham Verma | December 30, 2020 | Updated 16:16 IST Realme 7 Interested users can fill out a form to get the update. Realme recently rolled out Realme UI 2.0 stable version for X50 Pro. Realme UI 2.0, which is based on Android 11, is now available on X50 Pro 5G via the ...

AIM ImmunoTech Inc. AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple type...

HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel TUCSON, Ariz., Dec. 18, 2020 — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its prototype whole transcr...

Share: NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn® (MSC-NTF cells)  Expanded Access Program (EAP) for  patients with amyotrophic lateral sclerosis (ALS) who completed the Companys recently concluded pivotal Phase 3 clinical trial and meet specific eligibility requirements. The protocol for...